A Study to Evaluate Efficacy and Safety of Pazopanib Versus Sunitinib for the Treatment of Asian Subjects With Locally Advanced and/or Metastatic Renal Cell Carcinoma
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 05 Jun 2018
At a glance
- Drugs Pazopanib (Primary) ; Sunitinib
- Indications Renal cell carcinoma
- Focus Therapeutic Use
- Sponsors GlaxoSmithKline; Novartis
- 05 Jun 2018 Results (n=209) of pooled subgroup analysis (NCT00720941 and NCT01147822) presented at the 54th Annual Meeting of the American Society of Clinical Oncology
- 01 Mar 2017 Planned End Date changed from 1 Sep 2017 to 30 Sep 2019.
- 27 Feb 2017 Planned End Date changed from 1 Jun 2017 to 1 Sep 2017.